Recruiting
Phase 2

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Sponsor:

AstraZeneca

Code:

NCT05061550

Conditions

Non-small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Durvalumab

Oleclumab

Monalizumab

Dato-DXd

AZD0171

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information